Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth and Progenics get EC approval for Relistor

Wyeth and Progenics get EC approval for Relistor

4th July 2008

Wyeth Pharmaceuticals and Progenics have received marketing approval from the European Commission for Relistor (methylnaltrexone bromide).

The subcutaneous injection has been approved as a treatment for opioid-induced constipation in patients with advanced illness receiving palliative care for their condition who have not responded to usual laxative therapy.

It is the first compound to be approved in this indication in the EU and will be rolled out on a country-by-country basis, starting from this month.

Relisor is a peripherally-acting mu-opoid receptor antagonist that decreases the constipating effects of such drugs without affecting their pain-relieving abilities.

Joseph M Mahady, president of Wyeth Pharmaceuticals, said: “We are proud to be able to offer this new innovation to physicians and health care providers caring for palliative care patients with advanced illness.”

He added that the company is pleased to have received regulatory approval for the drug from Canada, the US and Europe in quick succession as these territories are developed markets for the use of opioids in palliative care.

In May 2008, Wyeth reported the publication of positive phase III results for Relisotr in the New England Journal of Medicine.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.